IL6 and neoplasm: The activation of the NF-κB signaling pathway in TAM and MDSCs induces the expression of pro-inflammatory factors (IL-10) and chemokines (CCL17, CCL2), while inhibiting the expression of inflammatory cytokines (TNF α, IL-1, IL-6, etc.), leading to M2 macrophage activation and tumor evasion (238, 239).